Loading market dashboard
CDT Equity Inc.
CDTHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that the Company received a written notice (“Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2026 indicating that the Company did not timely file its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”), as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”).
SHENZHEN, China, May 28, 2026 (GLOBE NEWSWIRE) -- CDT Environmental Technology Investment Holdings Limited (NASDAQ: CDTG) (the “Company”), a leading provider of waste treatment systems and services throughout China, today announced that its Board of Directors (the “Board”) has approved the implementation of a 1-for-25 share consolidation (the “Share Consolidation”) of the Company's Class A ordinary shares, par value $0.0025 per share, and Class B ordinary shares, par value $0.0025. The Share Consolidation is intended to increase the per-share trading price of the Company's Class A ordinary shares and to assist the Company in maintaining compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 27, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that the patent covering the use of AZD5904 in male infertility has now been granted in Canada, completing the approval of this patent in all key pharmaceutical target markets.
YE 2025 total revenues of $18.2 million, representing a decrease of approximately $11.5 million or a 38.8% decrease year-over-year YE 2025 reported net loss of ($10.3) million driven by increase in stock-based compensation of $1.7 million and the recording of a provision for credit losses, net of recoveries, of approximately $14.7 million Restructuring activities, previously implemented, have streamlined operations and improved efficiency, supporting a more competitive cost structure As of March 31, 2026, the Company had three projects in backlog with a total provisional contract value of approximately US$26.8 million and currently has bids on two new wastewater treatment system projects Prioritizing investments in accelerated innovation with a focus on new energy opportunities SHENZHEN, China, May 15, 2026 (GLOBE NEWSWIRE) -- CDT Environmental Technology Investment Holdings Limited (Nasdaq: CDTG) (“CDT”, the “Company”, or “we”), a leading provider of waste treatment systems and services throughout China, announced to today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”) on May 15, 2026. The annual report on Form 20-F, which contains CDT's audited consolidated financial statements, can be accessed through the SEC's website at www.sec.gov or CDT's website at https://www.cdthb.cn.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the filing of a new Substance of Matter (SOM) patent covering two established compounds within the cystic fibrosis market.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 06, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that AZD5904, a potent inhibitor of human Myeloperoxidase, originally licensed from AstraZeneca, has progressed into the Patent Cooperation Treaty (“PCT”) phase, marking a significant step in the globalisation of its intellectual property (IP) protection.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today provides a strategic update outlining its positioning as a multi-pathway value creation business spanning a pharmaceutical asset portfolio, proprietary solid-form intellectual property and artificial intelligence-driven indication discovery.
• CDT Equity stock is among today's top performers. What's behind CDT gains?
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of CDT Environmental Technology Investment Holdings Ltd. (NASDAQ: CDTG) resulting from allegations that CDT Environmental may have issued materially misleading business information to the investing public. So what: If you purchased CDT Environmental securities you may be entitled to compensation without payment of any out of pocke.
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of CDT Environmental Technology Investment Holdings Ltd. (NASDAQ: CDTG) resulting from allegations that CDT Environmental may have issued materially misleading business information to the investing public. So what: If you purchased CDT Environmental securities you may be entitled to compensation without payment of any out of pocke.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the publication of its research paper titled “PRISM: cross-species connectivity mapping of plant intervention and stress signatures for translational agriculture.
CDT Equity Inc. (NASDAQ: CDT - Get Free Report) was the target of a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 129,934 shares, a decrease of 26.9% from the February 26th total of 177,766 shares. Approximately 6.3% of the company's shares are short sold.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced the filing of two new patent applications that further expand the Company's intellectual property portfolio surrounding tapinarof, a drug currently approved for the treatment of psoriasis and atopic dermatitis.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) announces that its board of directors has approved a 1-for-25 reverse stock split of the Company's common stock.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 23, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that it has completed initial signature mapping of its asset portfolio against Sarborg Limited's recently curated rare disease database, identifying multiple high-potential opportunities across a range of rare and underserved indications.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that all proposals put forth at the Special Meeting of Stockholders of CDT, held on Tuesday, March 17, 2026, were duly passed by the stockholders.
CDT Equity Inc. (NASDAQ: CDT - Get Free Report) was the target of a significant growth in short interest in February. As of February 27th, there was short interest totaling 177,766 shares, a growth of 140.0% from the February 12th total of 74,063 shares. Approximately 8.4% of the shares of the stock are sold short. Based
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 12, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the expansion of its proprietary AI Signature Agent platform through the curation of a rare disease signature database.
